Vycellix, Avectas partner for product development

By The Science Advisory Board staff writers

March 26, 2020 -- Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

The companies will partner on the use of Vycellix's RNA immunomodulator VY-M for immunodiscovery cell and gene therapy with Avectas' Solupore cell engineering platform to address the current limitations of cell-based therapies and the need to accelerate manufacturing processes, reduce manufacturing costs, and improve patient outcomes.

Vycellix and Avectas also are currently collaborating with NextGenNK, a newly established competence center for the development of next-generation natural killer cell-based cancer immunotherapies based at Karolinska Institutet in Stockholm, Sweden.


Copyright © 2020 scienceboard.net


Conferences
BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter